Recursion Pharmaceuticals

Recursion Pharmaceuticals is a clinical-stage TechBio company at the forefront of AI-driven drug discovery, revolutionizing the field with its innovative approach. By combining artificial intelligence, machine learning, and extensive biological and chemical datasets, Recursion accelerates the drug discovery process, setting new standards in therapeutic development. At the heart of this approach is the Recursion Operating System (OS), a platform that continuously expands one of the world’s largest proprietary biological and chemical datasets. This platform leverages sophisticated machine-learning algorithms to analyze trillions of searchable relationships across biology and chemistry, unconstrained by human bias. Recursion's capabilities extend to conducting millions of wet lab experiments weekly and operating one of the world's most powerful supercomputers. This technological prowess enables the company to identify promising drug candidates with unprecedented speed and accuracy. In October 2024, Recursion achieved a significant milestone with FDA approval to begin phase 1 trials of an AI-discovered cancer treatment. Using its AI-enabled drug discovery platform, the company identified a novel target and moved from discovery to IND approval in less than 18 months, a process that typically takes years. This breakthrough demonstrates the potential of AI to dramatically accelerate drug discovery and reduce costs. The success of Recursion Pharmaceuticals has attracted partnerships with major pharmaceutical companies, positioning it as a leader in the emerging field of AI-driven drug development. The company offers a robust pipeline of clinical and preclinical drug candidates, all driven by AI insights and biological data. By integrating recursive thinking and cutting-edge technology, Recursion not only accelerates drug discovery but also enhances the precision and personalization of treatments. As Recursion continues to push the boundaries of medical research, it paves the way for innovative solutions that promise improved patient outcomes and a new era in therapeutic development.